Skip to main content
BASKHANBIOPharma Inc. logo

BASKHANBIOPharma Inc. — Investor Relations & Filings

Ticker · 354390 ISIN · KR7354390007 KO Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2023-06-20 Regulatory Filings
Country KR South Korea
Listing KO 354390

About BASKHANBIOPharma Inc.

http://www.baskhanbio.com/

BASKHANBIOPharma Inc. is a pharmaceutical company focused on pain management and improving patient quality of life. The company engages in the manufacture, sale, and distribution of a diverse product portfolio. Its core offerings include prescription drugs, over-the-counter (OTC) medicines, and medical devices, with a particular emphasis on products used before, during, and after surgical procedures. In addition to its primary pharmaceutical and medical device operations, the company's business areas also encompass health functional foods and cosmetics.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement (under 1,000 characters) reporting the results of an Investor Relations (IR) meeting held by Baskan BioPharm. It lists the date, location, attendees, and agenda of the meeting, and confirms that the IR materials have been posted to the Korea Exchange's disclosure system. Since it is a brief notification regarding the occurrence of an event and the availability of materials rather than the presentation itself, it falls under the Report Publication Announcement (RPA) category.
2023-06-20 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) meeting. It provides details such as the date, time, location, target audience, and purpose of the meeting. Since this is an announcement of an upcoming event rather than the presentation materials themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a standard corporate disclosure of an event.
2023-06-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회 결과' (Regular General Meeting of Shareholders Results) and provides a detailed breakdown of the agenda items voted upon, including the approval of financial statements, director appointments, and remuneration limits. This matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2023-03-27 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Supervisory Service/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and employee compensation via stock options is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for director/insider trading) or SHA (which is for general share issuance/capital changes).
2023-03-27 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2022 (Jan 1, 2022 to Dec 31, 2022) filed by Baskhanbio Pharma Inc. It contains detailed sections including company overview, history, capital changes, and governance information. In the context of Korean regulatory filings (DART), a 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K), as it provides a full yearly summary of company activity and financial performance. FY 2022
2023-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Baskan Bio Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, etc.) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the submission of the audit report to the regulator, rather than the full, multi-page audit report document itself. Therefore, it fits the definition of a regulatory filing. FY 2022
2023-03-14 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.